This highlighted study looks at using these 2 therapies concurrently for this infection.
Tiffany Lee, PharmD, BCIDP
Advertisement
Articles by Tiffany Lee, PharmD, BCIDP
Interests have recently skewed toward the use of carbapenem-sparing regimens in light of growing selection for carbapenem-resistant organisms.
Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection
Advertisement
Latest Updated Articles
Double Trouble: Assessing the Impact of Combining Daptomycin and Fosfomycin for MRSA BacteremiaPublished: September 18th 2020 | Updated:
- Differences in C difficile Diagnostics Blunt the Benefits of Bezlotoxumab
Published: December 3rd 2019 | Updated:
- Piperacillin/Tazobactam for the Treatment of ESBL Pyelonephritis: A Redemption Arc
Published: April 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
2
Meet SIDP’s President Elect: Lisa Dumkow, PharmD, FIDP, BCIDP
3
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
4
Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections
5
